Vitamin D Receptor (VDR)

← Back to Lab Reference Library

Biomarker: Vitamin D Receptor (VDR) Gene  |  Category: Genetic Markers  |  Test type: SNP genotyping  |  Specimen: Saliva or blood (DNA)

1. What Is the Vitamin D Receptor?

The vitamin D receptor (VDR) is a nuclear transcription factor encoded by the VDR gene on chromosome 12. It belongs to the nuclear receptor superfamily and functions as the intracellular receptor through which vitamin D - specifically its active form, 1,25-dihydroxyvitamin D3 (calcitriol) - exerts its biological effects. When calcitriol binds to VDR, the complex moves into the cell nucleus, heterodimerizes with the retinoid X receptor (RXR), and binds to vitamin D response elements (VDREs) in the promoter regions of target genes to regulate their transcription.

The scope of VDR's regulatory influence is vast. Over 200 target genes have been identified in various tissues, governing processes as diverse as calcium absorption in the intestine, parathyroid hormone suppression, T-regulatory cell development in the thymus, insulin secretion in pancreatic beta cells, renin-angiotensin system regulation in the kidney, and cell cycle arrest and differentiation in epithelial tissues. This breadth makes VDR one of the most biologically influential nuclear receptors in the human body and explains why vitamin D - properly understood as a steroid prohormone rather than simply a vitamin - has such wide-ranging effects on health and disease.

2. Key VDR Polymorphisms and Their Effects

Single-nucleotide polymorphisms (SNPs) are single-base variations in the DNA sequence that occur in at least 1% of the population. VDR has been extensively studied for SNPs that alter its expression level, binding affinity for calcitriol, or downstream transcriptional activity. Four variants have accumulated the most clinical research:

SNP	rs Number	Location	Effect
FokI	rs2228570	Exon 2 (coding)	The F allele produces a shorter VDR protein with higher transcriptional activity. The f allele produces a longer, less efficient receptor. FokI directly alters the receptor protein sequence.
BsmI	rs1544410	Intron 8	Affects mRNA stability and splicing efficiency. The b allele is associated with higher VDR expression in some tissues. B allele linked to lower expression and potentially lower bone density in some studies.
ApaI	rs7975232	Intron 8	Located near BsmI; often inherited together. Associated with altered VDR mRNA stability. Effects on immune function and bone metabolism studied extensively.
TaqI	rs731236	Exon 9 (synonymous)	Silent coding variant but affects mRNA stability. T allele associated with higher receptor expression. Inherited in haplotype with BsmI and ApaI in most populations.

3. How VDR Variants Affect Vitamin D Requirements

The central clinical implication of VDR polymorphisms is that serum 25-OH vitamin D levels do not tell the complete story of vitamin D sufficiency. Two patients can have identical 25-OH vitamin D levels of 55 ng/mL - one with highly efficient VDR signaling who responds robustly at that level, and another with reduced-function VDR variants who experiences inadequate downstream gene activation at the same level and effectively requires 70-80 ng/mL to achieve equivalent biological effects.

This mechanistic insight resolves a common clinical puzzle: why do some patients supplement aggressively with vitamin D but continue to show poor vitamin D-related outcomes - ongoing autoimmune flares, impaired calcium absorption, inadequate immune modulation, or persistently low calcitriol - despite serum 25-OH vitamin D levels that appear adequate? VDR variants that reduce receptor efficiency are a major explanation, and recognizing them allows targeted intervention.

4. Clinical Conditions Associated with VDR Variants

• Autoimmune diseases: VDR variants, particularly FokI and BsmI, are associated with susceptibility to multiple sclerosis, rheumatoid arthritis, type 1 diabetes, and systemic lupus erythematosus - reflecting vitamin D's role in promoting T-regulatory cells that suppress autoimmune responses
• Hashimoto's thyroiditis: VDR polymorphisms are overrepresented in Hashimoto's patients and may contribute to the impaired immune tolerance that allows anti-thyroid autoimmunity to persist; higher serum vitamin D targets are often clinically indicated in these patients
• Osteoporosis and fracture risk: BsmI and TaqI variants predict bone mineral density and fracture risk in postmenopausal women independently of serum vitamin D levels, reflecting direct VDR effects on osteoblast function and calcium absorption efficiency
• Colorectal and breast cancer risk: multiple meta-analyses associate VDR variants with altered colorectal and breast cancer susceptibility, consistent with vitamin D's role in promoting cell differentiation and suppressing proliferation in epithelial tissues
• Type 2 diabetes and metabolic syndrome: FokI variants are associated with impaired insulin secretion and higher type 2 diabetes risk, reflecting VDR expression on pancreatic beta cells where calcitriol stimulates insulin gene transcription
• Cardiovascular disease: VDR variants are associated with renin-angiotensin system regulation and hypertension risk; calcitriol suppresses renin transcription through VDR, and variants that reduce this effect may contribute to blood pressure dysregulation
• CIRS and biotoxin illness: patients with chronic inflammatory response syndrome frequently show VDR dysfunction - both polymorphic and acquired - contributing to impaired immune regulation and difficulty clearing biotoxin-driven inflammation
• Vitamin D-resistant rickets: severe homozygous loss-of-function VDR mutations cause hereditary vitamin D-resistant rickets (HVDRR), a rare but clinically important condition requiring calcitriol therapy

5. VDR Testing - What Is Measured and How

VDR polymorphism testing is performed through genomic DNA analysis - typically from a saliva sample or blood draw. The DNA is analyzed by polymerase chain reaction (PCR) followed by restriction fragment length polymorphism (RFLP) analysis, or more commonly by modern SNP chip or next-generation sequencing platforms. Results are reported as genotypes for each SNP - homozygous reference, heterozygous, or homozygous variant - and can be contextualized as estimated functional impact on VDR activity.

6. How VDR Results Change Clinical Management

VDR Finding	Clinical Implication
Reduced-function FokI (ff genotype)	Lower receptor transcriptional efficiency. Target serum 25-OH vitamin D at 70-90 ng/mL rather than standard 50-60 ng/mL. Consider monitoring 1,25-OH vitamin D and parathyroid hormone to assess functional response.
High-risk BsmI-TaqI haplotype	Higher autoimmune disease susceptibility and potentially lower bone density response to vitamin D. More aggressive supplementation and cofactor repletion (K2, magnesium) may be warranted.
Multiple reduced-function VDR variants	Consider calcitriol supplementation alongside cholecalciferol to deliver active hormone directly rather than relying on conversion efficiency. Monitor calcium and kidney function closely with calcitriol use.
Efficient VDR genotype with low 25-OH vitamin D	Inadequate sun exposure and dietary intake are the primary drivers. Standard supplementation protocols are appropriate; genetic enhancement of receptor is not limiting factor.
VDR variants in CIRS patient	May require Shoemaker-protocol VIP peptide therapy in addition to vitamin D optimization to restore VDR pathway function in biotoxin-disrupted immune signaling.

7. Supporting VDR Pathway Function Beyond Supplementation

Even in patients with reduced-function VDR variants, several cofactors and interventions support maximum receptor function and downstream signaling. Magnesium is required at multiple steps in vitamin D metabolism - conversion of 25-OH vitamin D to calcitriol is magnesium-dependent, and magnesium deficiency impairs VDR pathway function even when serum vitamin D levels are adequate. Vitamin K2 works synergistically with vitamin D through separate nuclear receptor pathways to direct calcium into bone rather than soft tissue - particularly important in patients on high-dose vitamin D therapy. Zinc supports VDR gene transcription, and boron reduces 25-OH vitamin D degradation, effectively increasing the amount available for conversion to calcitriol.

8. Related Labs and Tests

9. Frequently Asked Questions